Argentina is among the top 20 pharmaceutical markets globally, ranking third in Latin America, with estimated drug retail sales of USD 6.1bn in 2017. The country also features a large and ageing population, a relatively developed public health system, and a small but consolidated private health insurance system on the back of a strong middle class. Despite its well diversified production base and solid demand fundamentals deriving from Argentina’s changing disease and epidemiological profiles, the country’s pharmaceutical industry is becoming less and less able to compete with foreign producers, largely thanks to stubbornly high inflation and rising production costs. This has resulted in a growing reliance on imported drugs and in chronic trade deficits in pharmaceuticals, which reached USD 1.6bn in 2017.

01 EXECUTIVE SUMMARY 

02 SECTOR IN FOCUS 

03 COMPETITIVE LANDSCAPE

04 COMPANIES IN FOCUS

05 REGULATORY ENVIRONMENT 

06 PHARMACEUTICALS 

07 HEALTHCARE

08 RETAIL CHANNELS